Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Walczak, Henning, Miller, Robert E., Ariail, Kiley, Gliniak, Brian, Griffith, Thomas S., Kubin, Marek, Chin, Wilson, Jones, Jon, Woodward, Anne, Le, Tiep, Smith, Craig, Smolak, Pam, Goodwin, Raymond G., Rauch, Charles T., Schuh, JoAnn C.L., Lynch, David H.·1999·Nature Medicine
DOI 10.1038/5517

Cited by (1,003)

Items 801–900 of 1,003

  1. Breast Tumor Xenografts: Diffusion-weighted MR Imaging to Assess Early Therapy with Novel Apoptosis-Inducing Anti-DR5 Antibody
    Hyunki Kim, Desiree E. Morgan, Huadong Zeng, William E. Grizzle, Jason M. Warram, Cecil R. Stockard, Deli Wang, Kurt R. Zinn · 2008 · Radiology
  2. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand
    Simon R. Mucha, Antonia Rizzani, Alexander L. Gerbes, Peter Čamaj, Wolfgang Erwin Thasler, Christiane J. Bruns, S.T. Eichhorst, Eike Gallmeier, Frank Thomas Kolligs, Burkhard Göke et al. · 2008 · Gut
  3. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells
    Takaaki Matsui · 2006 · Carcinogenesis
  4. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts
    Irina V. Balyasnikova, Sherise Desiree Ferguson, Yu Han, Fei‐Fei Liu, Maciej S. Lesniak · 2011 · Cancer Letters
  5. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia
    James B. Johnston, Albert F. Kaboré, Jeanna Strutinsky, Xiaojie Hu, James T. Paul, Dianne M Kropp, Brenda Kuschak, Asher Begleiter, Spencer Bruce Gibson · 2003 · Oncogene
  6. Macrophages From Cancer Patients: Analysis of TRAIL, TRAIL Receptors, and Colon Tumor Cell Apoptosis
    Jean‐Philippe Herbeuval, Claude Lambert, Odile Sabido, Michèle Cottier A, P. Fournel, Michel Dy, Christian Genin · 2003 · JNCI Journal of the National Cancer Institute
  7. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention
    Manzoor Ahmad, Yufei Shi · 2000 · Oncogene
  8. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update
    Sarah H. Beachy, Elizabeth A. Repasky · 2008 · Cancer Immunology Immunotherapy
  9. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
    Jenny N. H. G. Ho, Dominik Schmidt, Theresa Lowinus, Jeongmin Ryoo, Elaine-Pashupati Dopfer, Nicolás Gonzalo Núñez, Sara Costa-Pereira, Cristina Toffalori, Marco Punta, Viktor Fetsch et al. · 2022 · Blood
  10. Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
    Lia Elena Perez, Nancy Parquet, Kenneth H. Shain, Ramadevi Nimmanapalli, Melissa Alsina, Claudio Anasetti, William S. Dalton · 2008 · The Journal of Immunology
  11. Nitrosative stress in cancer therapy
    David, G. Hirst · 2007 · Frontiers in bioscience
  12. Molecular Pathogenesis of Cholangiocarcinoma
    Giammarco Fava, Ivano Lorenzini · 2011 · International Journal of Hepatology
  13. Modulation of CD4+ T-cell activation by CD95 co-stimulation
    Maren Paulsen, S. Valentin, Blurton-Jones Mathew, Sabine Adam‐Klages, Uwe Bertsch, Inna N. Lavrik, Peter H. Krammer, Dieter Kabelitz, Ottmar Janßen · 2010 · Cell Death and Differentiation
  14. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells
    David Llobet‐Navàs, Núria Eritja, Mario Encinas, Núria Llecha, Andrée Yeramian, J Pallares, Anabel Sorolla, Francisco Javier Gonzalez-Tallada, Xavier Matías‐Guiu, Xavier Dolcet · 2007 · Oncogene
  15. A New C-Terminal Cleavage Product of Procaspase-8, p30, Defines an Alternative Pathway of Procaspase-8 Activation
    Julia C. Hoffmann, Alexander Pappa, Peter H. Krammer, Inna N. Lavrik · 2009 · Molecular and Cellular Biology
  16. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells
    Sung‐Chul Lim, Hong‐Quan Duong, Jeong Eun Choi, Tae-Bum Lee, Ju‐Hee Kang, Seung Hyun Oh, Song Iy Han · 2011 · Carcinogenesis
  17. Butein Sensitizes Human Hepatoma Cells to TRAIL-Induced Apoptosis via Extracellular Signal-Regulated Kinase/Sp1–Dependent DR5 Upregulation and NF-κB Inactivation
    Dong‐Oh Moon, Mun-Ock Kim, Yung Hyun Choi, Gi‐Young Kim · 2010 · Molecular Cancer Therapeutics
  18. Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy
    Javier Naval, Diego de Miguel, Ana Gallego-Lleyda, Alberto Anel, Luis Martínez‐Lostao · 2019 · Cancers
  19. The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer
    Amanda Dutton, Lawrence S. Young, Paul Gerard Murray · 2006 · Expert Opinion on Therapeutic Targets
  20. The role of TRAIL/TRAIL receptors in central nervous system pathology
    Orhan Aktaş · 2007 · Frontiers in bioscience
  21. Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism
    Nieves Varela, Cristina Muñoz‐Pinedo, Carmen Ruiz‐Ruiz, Gema Robledo, Miriam Pedroso, Abelardo López‐Rivas · 2001 · Journal of Biological Chemistry
  22. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis
    Chao Wu Xiao, B FENGYANG, Jin Hyang Song, Howard Schulman, L LI, Chunhai Hao · 2004 · Experimental Cell Research
  23. Inhibition of the NF-κB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells
    Bahri Karaçay, Salih Şanlıoğlu, Thomas S. Griffith, Anthony David Sandler, Daniel J. Bonthius · 2004 · Cancer Gene Therapy
  24. Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage
    V. Courtney Broaddus, Tobias B. Dansen, Keith S. Abayasiriwardana, Shannon M. Wilson, Andrew J. Finch, Lamorna Brown Swigart, Abigail E. Hunt, Gérard I. Evan · 2004 · Journal of Biological Chemistry
  25. Interferon-alpha Subtype 11 Activates NK Cells and Enables Control of Retroviral Infection
    Kathrin Sutter, Jara J. Joedicke, Andreas Meryk, Mirko Trilling, Sandra Francois, Janine Duppach, Anke R.M. Kraft, Karl Sebastian Lang, Ulf Dittmer · 2012 · PLoS Pathogens
  26. TRAIL receptor mediates inflammatory cytokine release in an NF-κB-dependent manner
    Wanhu Tang, Weimin Wang, Yaxi Zhang, Shilian Liu, Yanxin Liu, Dexian Zheng · 2009 · Cell Research
  27. PEGylated TNF-Related Apoptosis-Inducing Ligand (TRAIL) Analogues: Pharmacokinetics and Antitumor Effects
    Tae Hyung Kim, Yu Seok Youn, Hai Hua Jiang, Seulki Lee, Xiaoyuan Shawn Chen, Kang Choon Lee · 2011 · Bioconjugate Chemistry
  28. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells
    Shunchao Yan, Xiujuan Qu, XU Chong-an, Zhitu Zhu, Lingyun Zhang, Ling Xu, Na Song, Yuee Teng, Yunpeng Liu · 2012 · Journal of Cancer Research and Clinical Oncology
  29. Nuclear drug delivery to target tumour cells
    Kylie M. Wagstaff, David A. Jans · 2009 · European Journal of Pharmacology
  30. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC -independent mechanism in human malignant tumor cells
    Jun Hee Lim, Jung‐Won Park, Kyeong Sook Choi, Y. B. Park, Taeg Kyu Kwon · 2008 · Carcinogenesis
  31. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells
    Katharina Hammer, Adam Kazcorowski, Li Liu, Michael Behr, Peter Schemmer, Ingrid Herr, Dirk M. Nettelbeck · 2015 · International Journal of Cancer
  32. Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity
    Haizhen Wang, Jennifer Sarah Davis, Xiangwei Wu · 2014 · Molecular Cancer Therapeutics
  33. Current treatment for Ewing’s sarcoma
    Mihir M. Thacker, Harry Thomas Temple, Sean P. Scully · 2005 · Expert Review of Anticancer Therapy
  34. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms
    Marie D. Ralff, Christina Leah B. Kline, Ozan C. Küçükkase, Jessica Wagner, Bora Lim, David T. Dicker, Varun V. Prabhu, Wolfgang Oster, Wafik S. El‐Deiry · 2017 · Molecular Cancer Therapeutics
  35. The Murine Natural Cytotoxic Receptor NKp46/NCR1 Controls TRAIL Protein Expression in NK Cells and ILC1s
    Sam Sheppard, Iona S. Schuster, Christopher E. Andoniou, Clément Cocita, Thomas Adejumo, Sam K. P. Kung, Joseph Chai-Yuen Sun, Mariapia A. Degli‐Esposti, Nadia Guerra · 2018 · Cell Reports
  36. α‐Fetoprotein causes apoptosis in tumor cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase‐3‐like proteases
    Elena I. Dudich, Lidia Semenkova, Igor V. Dudich, Elena Gorbatova, Natasha Tochtamisheva, Edward Tatulov, M. A. Nikolaeva, Gennady Tikhonovich Sukhikh · 1999 · European Journal of Biochemistry
  37. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Δ12, 14 prostaglandin J2 production
    Hiroo Hasegawa, Yasuaki Yamada, Kanki Komiyama, Masahiko Hayashi, Masami Ishibashi, Toshiaki Sunazuka, Takeshi Izuhara, Kazuyuki Sugahara, Kazuto Tsuruda, Masato Masuda et al. · 2007 · Blood
  38. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Ali R. Jazirehi, Chuen‐Pei Ng, Xiao-Hu Gan, Gary John Schiller, Benjamin Bonavida · 2001 · PubMed
  39. Enhancement of Apo2L/TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)–induced apoptosis in non–small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
    Steffen Frese, Thomas Brunner, Mathias Gugger, Aima N. Uduehi, Ralph Alexander Schmid · 2002 · Journal of Thoracic and Cardiovascular Surgery
  40. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
    Marion Déjosez, U. Ramp, Csaba Mahotka, Andreas H. Krieg, Henning Walczak, Helmut Erich Gabbert, C D Gerharz · 2000 · Cell Death and Differentiation
  41. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer
    Luis Martínez‐Lostao, Isabel Marzo, Alberto Anel, Javier Naval · 2012 · Biochemical Pharmacology
  42. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
    David Llobet‐Navàs, Núria Eritja, Andrée Yeramian, J. Pallares, Anabel Sorolla, M. Domingo, Marı́a Santacana, Francisco Javier Gonzalez-Tallada, Xavier Matías‐Guiu, Xavier Dolcet · 2010 · European Journal of Cancer
  43. Emerging role of tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) as a key regulator of inflammatory responses
    Adam Collison, Paul S. Foster, Joërg Mattes · 2009 · Clinical and Experimental Pharmacology and Physiology
  44. Polyphenols Isolated from Propolis Augment TRAIL-Induced Apoptosis in Cancer Cells
    Ewelina Szliszka, Wojciech Król · 2013 · Evidence-based Complementary and Alternative Medicine
  45. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
    Ewelina Szliszka, Bogdan Mazur, Grzegorz Zydowicz, Zenon Paweł Czuba, Wojciech Król · 2010 · Folia Histochemica et Cytobiologica
  46. Clusterin mediates TRAIL resistance in prostate tumor cells
    David Andrew Sallman, Xianghong Chen, Bin Zhong, Danielle L. Gilvary, Junmin Zhou, Sheng Wei, Julie Y. Djeu · 2007 · Molecular Cancer Therapeutics
  47. Effective Combination Therapy for Malignant Glioma with TRAIL-Secreting Mesenchymal Stem Cells and Lipoxygenase Inhibitor MK886
    Seong Muk Kim, Ji Sun Woo, Chang Hyun Jeong, Chung Heon Ryu, Jung Yeon Lim, Sin‐Soo Jeun · 2012 · Cancer Research
  48. NFκB-dependent Down-regulation of Tumor Necrosis Factor Receptor-associated Proteins Contributes to Interleukin-1-mediated Enhancement of Ultraviolet B-induced Apoptosis
    Birgit Pöppelmann, Kerstin Klimmek, Elwira A. Strozyk, Reinhard Voß, Thomas Schwarz, Dagmar Kulms · 2005 · Journal of Biological Chemistry
  49. Mutation analysis of the apoptotic “death‐receptors” and the adaptors TRADD and FADD/MORT‐1 in osteosarcoma tumor samples and osteosarcoma cell lines
    Markus J. Dechant, Jörg Fellenberg, C.G. Scheuerpflug, V. Ewerbeck, Klaus‐Michael Debatin · 2004 · International Journal of Cancer
  50. Caspase Regulation in Non–Small Cell Lung Cancer and its Potential for Therapeutic Exploitation
    Dean Anthony Fennell · 2005 · Clinical Cancer Research
  51. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells.
    George Kulik, James P. Carson, Tomáš Vomastek, K Overman, Barry D. Gooch, Srinivasa Murty Srinivasula, Emad S. Alnemri, Gabriel Núñez, Michael J. Weber · 2001 · PubMed
  52. Role of NF-κB Activity in Apoptotic Response of Keratinocytes Mediated by Interferon-γ, Tumor Necrosis Factor-α, and Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand
    Jian‐Zhong Qin, Patricia E. Bacon, Vijaya Chaturvedi, Brian J. Nickoloff · 2001 · Journal of Investigative Dermatology
  53. Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis
    Amnon Zisman, Chuen‐Pei Ng, Allan J. Pantuck, Benjamin Bonavida, Arie S. Belldegrun · 2001 · Journal of Immunotherapy
  54. Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.
    Khondoker M. Akram, Nicola J Lomas, Nicholas Robert Forsyth, M A Spiteri · 2014 · Europe PMC (PubMed Central)
  55. Targeted polymeric nanoparticles for cancer gene therapy
    Jayoung Kim, David R. Wilson, Camila Gadens Zamboni, Jordan J. Green · 2015 · Journal of drug targeting
  56. Luteolin enhances TNF-related apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model
    Jiaqi Yan, Qiong Wang, Xuelian Zheng, Hong Sun, Yuqiong Zhou, Daoxia Li, Yong Lin, Xia Wang · 2011 · Biochemical and Biophysical Research Communications
  57. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents
    Tania Sánchez‐Pérez, Gustavo Ortiz-Ferrón, Abelardo López‐Rivas · 2009 · Cell Death and Differentiation
  58. Triptolide and TRAIL Combination Enhances Apoptosis in Cholangiocarcinoma
    Kimberly A. Clawson, Daniel Borja–Cacho, Mara B. Antonoff, Ashok Kumar Saluja, Selwyn Maurice Vickers · 2010 · Journal of Surgical Research
  59. TNF-? induces changes in LDH isotype profile following triggering of apoptosis in PBL of non-Hodgkin?s lymphomas
    Vladimir Jurišić, V. Bumbaširević, Gordana M. Konjević, B. Djuričič, I Spužić · 2004 · Annals of Hematology
  60. Potential Application of Temozolomide in Mesenchymal Stem Cell-Based TRAIL Gene Therapy Against Malignant Glioma
    Seong Muk Kim, Ji Sun Woo, Chang Hyun Jeong, Chung Heon Ryu, Jae-Deog Jang, Sin‐Soo Jeun · 2014 · Stem Cells Translational Medicine
  61. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy
    Yi Zheng, Hongbo Chen, Xiaowei Zeng, Zhigang Liu, Xiaojun Xiao, Yongqiang Zhu, Dayong Gu, Lin Mei · 2013 · Nanoscale Research Letters
  62. Decursin enhances TRAIL‐induced apoptosis through oxidative stress mediated‐ endoplasmic reticulum stress signalling in non‐small cell lung cancers
    Jae Kwang Kim, Miyong Yun, Eun‐Ok Kim, Deok‐Beom Jung, Gunho Won, Bonglee Kim, Ji Hoon Jung, Sung‐Hoon Kim · 2015 · British Journal of Pharmacology
  63. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
    Tudor–Eliade Ciuleanu, Igor S. Bazin, Dan Lungulescu, Lucian Miron, Igor Bondarenko, Andrzej Deptała, Maribel Rodriguez‐Torres, Bruce J. Giantonio, N. L. Fox, Paul Stephen Wissel et al. · 2016 · Annals of Oncology
  64. TRAIL–NP hybrids for cancer therapy: a review
    Hanène Belkahla, Guillaume Herlem, Fabien Picaud, Tijani Gharbi, Miryana Hémadi, Souad Ammar, Olivier Micheau · 2017 · Nanoscale
  65. Apoptosis induction in renal cell carcinoma by TRAIL and γ-radiation is impaired by deficient caspase-9 cleavage
    U. Ramp, E Caliskan, Csaba Mahotka, Andreas H. Krieg, Sebastian Heikaus, Helmut Erich Gabbert, C D Gerharz · 2003 · British Journal of Cancer
  66. The Role of Death Receptor Ligands in Shaping Tumor Microenvironment
    Theresa L. Whiteside · 2006 · Immunological Investigations
  67. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance
    Brigitte M.T. Hougardy, John H. Maduro, Ate GJ van der Zee, Pax H.B. Willemse, Steven de Jong, Elisabeth G.E. de Vries · 2005 · The Lancet Oncology
  68. cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-κB Activation at the Death-inducing Signaling Complex in Human Keratinocytes
    Tina Wachter, Martin Ronald Sprick, Dominikus Hausmann, Andreas Kerstan, Kirsty McPherson, Giorgio Stassi, Eva‐B. Bröcker, Henning Walczak, Martin Leverkus · 2004 · Journal of Biological Chemistry
  69. 15-Deoxy-Δ12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARγ and potentiates TRAIL-induced apoptosis
    Susumu Nakata, Tatsushi Yoshida, Takumi Shiraishi, Mano Horinaka, Junji Kouhara, Miki Wakada, Toshiyuki Sakai · 2006 · Molecular Cancer Therapeutics
  70. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells
    Qin He, Xiuquan Luo, Ying Kao Huang, M. Saeed Sheikh · 2002 · Oncogene
  71. Steering anti-cancer drugs away from the TRAIL
    Shigekazu Nagata · 2000 · Nature Medicine
  72. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.
    Giulia Grisendi, Rita Bussolari, Elena Veronesi, Maria Serena Piccinno, Jorge Sans Burns, Giorgio De Santis, Pietro Loschi, Marco Pignatti, Fabrizio Di Benedetto, Roberto Ballarin et al. · 2011 · Europe PMC (PubMed Central)
  73. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity
    Shen Gao, Ding Ding, Shen Gao · 2011 · International Journal of Nanomedicine
  74. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation
    Ahmed Hamaï, Catherine Richon, Franck Meslin, Florence Faure, Audrey Kauffmann, Yann Lécluse, Abdelali Jalil, Lionel Larue, M.-F. Avril, Salem Chouaı̈b et al. · 2006 · Oncogene
  75. Effective gene–virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5
    Xin‐Yuan Liu, Song-Bo Qiu, Wei-Gou Zou, Zi-Fei Pei, Jin-Fa Gu, Chun-Xia Luo, Hong-Mei Ruan, Yu Chen, Yi-Peng Qi, Cheng Qian · 2005 · Molecular Therapy
  76. Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis
    Hongqin Zhuang, Weiwei Jiang, Wei Cheng, Kui Qian, Wei Dong, Lin Cao, Qilai Huang, Shufeng Li, Fei Dou, Jen‐Fu Chiu et al. · 2009 · Lung Cancer
  77. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
    Dae-Hee Lee, Ki Sa Sung, David L. Bartlett, Yong Tae Kwon, Yong Jun Lee · 2014 · Cellular Signalling
  78. Genetic determinants for chemo- and radiotherapy resistance in bladder cancer
    Andrea Mari, David D’Andrea, Mohammad M. Abufaraj, Beat Foerster, Shoji Kimura, Shahrokh François Shariat · 2017 · Translational Andrology and Urology
  79. The secretable form of trimeric TRAIL, a potent inducer of apoptosis
    Mihyang Kim, Timothy R. Billiar, Dai‐Wu Seol · 2004 · Biochemical and Biophysical Research Communications
  80. BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
    Daniel Diniz De Carvalho, Renata Binato, Welbert Oliveira Pereira, Janine Marie Gisele Leroy, M D Colassanti, Rodrigo Proto‐Siqueira, Ana Elisa B. Bueno-da-Silva, Marco Antonio Zago, Maria Aparecida Zanichelli, Eliana S. F. W. Abdelhay et al. · 2010 · Oncogene
  81. A “Stealth Effect”: Adenocarcinoma Cells Engineered to Express TRAIL Elude Tumor-Specific and Allogeneic T Cell Reactions
    Mirella Giovarelli, Piero Musiani, Gianni Garotta, Reinhard Ebner, Emma Di Carlo, Yun‐Soo Kim, Paola Cappello, Laura Maria Rigamonti, Paola Bernabei, Francesco Novelli et al. · 1999 · The Journal of Immunology
  82. Cancer chemopreventive role of fisetin: Regulation of cell signaling pathways in different cancers
    Ammad Ahmad Farooqı, Humaira Naureen, Rabbia Zahid, Lara Youssef, Rükset Attar, Baojun Xu · 2021 · Pharmacological Research
  83. LUCA-15/RBM5, a putative tumour suppressor, enhances multiple receptor-initiated death signals
    Nina D. Rintala‐Maki, Leslie C. Sutherland · 2004 · APOPTOSIS
  84. Inhibition of MKK7–JNK by the TOR Signaling Pathway Regulator-Like Protein Contributes to Resistance of HCC Cells to TRAIL-Induced Apoptosis
    In Sung Song, Soo Young Jun, Hee–Jun Na, Hyun–Taek Kim, So Young Jung, Ga‐Hee Ha, Young–Ho Park, Liang Zhe Long, Dae‐Yeul Yu, Jin‐Man Kim et al. · 2012 · Gastroenterology
  85. The pro‐metastatic role of bone marrow‐derived cells: a focus on MSCs and regulatory T cells
    Bong Ihn Koh, Yibin Kang · 2012 · EMBO Reports
  86. Role of Intracellular Glutathione in Cell Sensitivity to the Apoptosis Induced by Tumor Necrosis Factor α–Related Apoptosis-Inducing Ligand/Anticancer Drug Combinations
    Olivier Meurette, Luz Lefeuvre‐Orfila, Amélie Rébillard, Dominique Lagadic‐Gossmann, Marie‐Thérèse Dimanche‐Boitrel · 2005 · Clinical Cancer Research
  87. Exceptionally Potent Anti-Tumor Bystander Activity of an scFv:sTRAIL Fusion Protein with Specificity for EGP2 Toward Target Antigen-Negative Tumor Cells
    Edwin Bremer, Douwe Freerk Samplonius, Bart‐Jan Kroesen, Linda van Genne, Lou de Leij, Wijnand Helfrich · 2004 · Neoplasia
  88. Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs
    Darren Finlay, Mitchell Vamos, Marcos González‐López, Robert Ardecky, Santhi Reddy, Hongbin Yuan, Ying Su, Trina R. Cooley, Curt T. Hauser, Kate Welsh et al. · 2013 · Molecular Cancer Therapeutics
  89. Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway
    Wei Xin Liu, Chao Xu, Hongyan Zhao, Pengpeng Xia, Ruilong Song, Jianhong Gu, Xuezhong Liu, Jianchun Bian, Yan Yuan, Zongping Liu · 2015 · PLoS ONE
  90. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer
    Diego de Miguel, Ana Gallego-Lleyda, José María Ayuso, María Dolores Pejenaute‐Ochoa, Vidal Jarauta, Isabel Marzo, Luis José Fernández, Ignacio Ochoa, Blanca Conde, Alberto Anel et al. · 2016 · Cancer Letters
  91. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
    Eonju Oh, JinWoo Hong, Oh‐Joon Kwon, Chae‐Ok Yun · 2018 · Scientific Reports
  92. Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
    Harald Wajant · 2019 · Cancers
  93. Multi-functional gene ASY/Nogo/RTN-X/RTN4: Apoptosis, tumor suppression, and inhibition of neuronal regeneration
    Akihiro Watari, Masuo Yutsudo · 2003 · APOPTOSIS
  94. Caspases Target Only Two Architectural Components within the Core Structure of the Nuclear Pore Complex
    Monika Patre, Anja Tabbert, Daniela Hermann, Henning Walczak, Hans‐Richard Rackwitz, Volker C. Cordes, Elisa Ferrando‐May · 2005 · Journal of Biological Chemistry
  95. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors
    Christina Herrnring, Toralf Reimer, Udo Jeschke, Josef Makovitzky, K. Krüger, Bernhard Gerber, Dieter Kabelitz, K Friese · 2000 · Histochemistry and Cell Biology
  96. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
    Johnathan M. Lancaster, Robyn A. Sayer, Carrie Blanchette, Brian Calingaert, Regina S. Whitaker, Joellen Schildkraut, Jeffrey R. Marks, Andrew Berchuck · 2003 · PubMed
  97. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
    Subbiah, Vivek, Chawla, Sant P., Conley, Anthony P., Wilky, Breelyn A., Tolcher, Anthony, Lakhani, Nehal J., Berz, David, Andrianov, Vasily, Crago, William, Holcomb, Monica et al. · 2023 · Clinical Cancer Research
  98. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
    Sunil Sharma, Elisabeth G.E. de Vries, Jeffrey R. Infante, Corina N.A.M. Oldenhuis, Jourik A. Gietema, Lin Yang, Sanela Bilic, Katie Parker, Michael Goldbrunner, Jeffrey W. Scott et al. · 2013 · Investigational New Drugs
  99. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
    Irene Zinonos, Agatha Labrinidis, Michelle Lee, Vasilios Liapis, Shelley J. Hay, Vladimir Ponomarev, Peter Diamond, Andrew C.W. Zannettino, David M. Findlay, Andreas Evdokiou · 2009 · Molecular Cancer Therapeutics
  100. miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer
    Guanli Huang, Xiangjian Chen, Yefeng Cai, Xiaobo Wang, Chungen Xing · 2016 · Oncology Reports